**Core tip:** Differences in patient genetic backgrounds may influence the quality of the immune response and may result in different hepatitis B virus (HBV) infection outcomes. Toll-like receptor 7 (*TLR7*) is involved in the sensing of viruses and priming of the subsequent immune response. We investigated the association between copy number at the *TLR7* locus and genetic susceptibility to chronic HBV infection. Comparison of individuals with chronic and acute HBV revealed that low *TLR7* copy number was associated with chronic but not acute HBV in both males and females, though it was not associated with subsequent disease progression.

INTRODUCTION
============

The outcome of hepatitis B virus (HBV) infection is influenced by not only the virus but also the host\'s immune response and genetic diversity, including single nucleotide polymorphism (SNPs) and gene copy number variants (CNVs)\[[@B1]-[@B3]\]. Many studies support the idea that host genetic susceptibility plays an important role in determining the outcome of HBV infection\[[@B4]\]. Previous studies have shown that several SNP sites are associated with the development of chronic HBV infection and the progression of disease\[[@B5]-[@B7]\].

CNVs arise when individuals carry different numbers of copies of the same DNA sequence. These may be the result of deletions or duplications and insertions, and they typically cover about 15% of the human genome in each individual. CNVs are a common source of variation in the human genome and are known to play an important role in complex genetic diseases. In addition to affecting the copy number (CN) of a DNA sequence\[[@B8],[@B9]\], CNVs may affect gene expression through dosage and position effects, which may further influence an individual\'s disease susceptibility and progression\[[@B9]-[@B11]\]. In humans, CNVs have so far been identified as a hereditable source of susceptibility to complex diseases such as systemic lupus erythematosus (SLE), type 1 diabetes, HBV infection, and Alzheimer\'s disease\[[@B8],[@B12]\].

Toll-like receptors (TLRs) function as critical pattern recognition receptors (PRRs). TLRs recognize foreign pathogens as well as necrosis of endogenous substances, and play a role in both the innate and acquired immune responses\[[@B13]-[@B15]\]. TLRs are widely expressed in various tissues, with individual receptors exhibiting specific cell distributions. *TLR7* is a highly conserved gene on the X chromosome\[[@B16],[@B17]\], and its product is expressed primarily in dendritic cells (pDC), B cells, and macrophages. TLR7 recognizes single-stranded RNA through the MyD88-dependent signaling pathway, inducing pro-inflammatory factors and the production of type I interferon to mediate the body\'s non-specific immune response. Activation of TLR7 initiates downstream signaling cascades through transcription factors such as interferon regulatory factor 7. This induces production of pro-inflammatory cytokines and chemokines, which are involved in various HBV infection outcomes, including spontaneous clearance and viral persistence. The role of *TLR7* CNVs in the outcome of HBV infection has not yet been investigated. In the present study, we categorized the groups according to gender, analyzed the *TLR7* CNVs, and found that there is indeed an association between the CN of the *TLR7* gene and genetic susceptibility to chronic HBV infection.

MATERIALS AND METHODS
=====================

Subjects
--------

A total of 923 Han Chinese individuals with HBV infection were enrolled in this study from 2010 to 2015. Following recruitment, all subjects gave informed consent for genetic analysis. Among the patients, 623 (495 males and 128 females) suffered from chronic HBV (CHB) infection. The remaining 300 (135 females and 165 males) were individuals with acute, self-limiting HBV (AHB) clearance and served as the control group. Average ages were 44.41 ± 15.32 years in the CHB group and 45.26 ± 15.54 years in the AHB group. All CHB patients fulfilled the diagnostic criteria of being positive for hepatitis B surface antigen (HBsAg) for a period of at least 6 mo, with serum HBV DNA level \> 1000 copies/mL. AHB patients were positive for hepatitis B surface antibody and hepatitis B core antibody but negative for HBsAg, and had no history of HBV vaccination. AHB controls were age-matched with CHB cases (*t* = 0.823, *P* \> 0.05). The 623 CHB patients were further classified according to disease progression: 253 patients had CHB only, 248 had liver cirrhosis (LC), and 122 had hepatocellular carcinoma (HCC). None of these patients had received anti-HBV therapy or had overlapping infections of hepatitis A, C, D, E, or G. CHB patients were also free from drug-induced hepatitis, alcoholic liver disease, fatty liver disease, and pregnancy. All of them have given consent for this study.

DNA extraction
--------------

Peripheral blood was collected from all subjects in vacuum blood tubes containing EDTA-K2. Genomic DNA was isolated from 2 mL whole blood using a Qiagen kit according to the manufacturer\'s instructions (Qiagen, Hilden, Germany) and was stored at -20 °C before CNV detection.

***Quantification of copy number at the* TLR7 *locus using AccuCopy assay***

CNs of the *TLR7* gene were measured using the AccuCopy method (Genesky Biotechnologies Inc., Shanghai, China). The basic molecular principle of AccuCopy\'s competitive PCR amplification was illustrated by Du et al\[[@B18]\]. Forward and reverse primers of target segments are listed in Table [1](#T1){ref-type="table"}.

###### 

Forward and reverse primers of *TLR7* target segments

  **Probe**   **Chromosome**   **Location (ref 37 database)[1](#T1FN1){ref-type="table-fn"}**   **Amplification length (sample, competitive)[2](#T1FN2){ref-type="table-fn"}**   **Primer binding region 1**   **Primer binding region 2**
  ----------- ---------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------- -----------------------------
  TLR7-2      ChrX             12885611-12885868                                                285 (+0, -2)                                                                     GGGCCCATCTCAAGCTGATCT         TAATGAAGGGGGCATGTCACAA
  TLR7-3      ChrX             12905987-12906102                                                143 (+0, -2)                                                                     GCACCTGTGATGCTGTGTGGTT        AGCACACAAGGGCCAAAGTGTG

GRCH37 primary reference assembly;

Sample: Sample DNA; competitive: Competitive DNA.

Competitive DNAs for the two references and 12 target segments were designed and synthesized as double-stranded DNA by Genesky Biotechnologies. Sequences of synthesized competitive DNAs were identical to their reference sequences in the human reference genome except for an introduced 2-bp deletion. The synthesized competitive DNAs for target and reference segments were first mixed with a defined amount of genomic DNA from each patient and then subjected to multiplex fluorescence competitive PCR amplification, which simultaneously amplified all reference and target segments from both the sample DNA and competitive DNA using multiple fluorescence-labeled primer pairs.

Thermal cycling conditions for multiplex competitive PCR amplification were based on the manufacturer\'s instructions. PCR products were diluted 20-fold before being loaded on to an ABI 3130XL (Applied Biosystems, Carlsbad, CA, United States) genetic analyzer for capillary electrophoresis. Raw data were analyzed by GeneMapper 4.0 (Applied Biosystems), and height data for all specific peaks were exported into a Microsoft Excel file where the peak ratio of sample DNA to competitive DNA (S/C) for each segment was calculated. After normalization using the reference segment\'s peak ratio, the CN ratio of each target segment to the reference was determined by the target\'s peak ratio divided by the reference\'s peak ratio.

Statistical analysis
--------------------

The distributions of *TLR7* CNs were compared between CHB patients and AHB control subjects using *χ^2^* test. *P* values, odds ratios (ORs), and 95% confidence intervals (CIs) were estimated using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, United States).

RESULTS
=======

Sample demographics
-------------------

*TLR7* gene CNs were analyzed and quantified in triplicate in 623 Chinese CHB patients and 300 Chinese AHB patients. Baseline patient characteristics are shown in Table [2](#T2){ref-type="table"}. While there were no significant age differences between AHB and CHB patients (including CHB, LC and HCC groups) (*t* = 0.823, *P* = 0.944 \> 0.05), there was a difference if the CHB group was divided into CHB, LC and HCC groups (F = 83.216, *P* \< 0.01).

###### 

Baseline characteristics of study patients

        ***n***   **Males/females**   **Age (yr)**    **95%CI**
  ----- --------- ------------------- --------------- -------------
  AHB   300       165/135             45.26 ± 15.54   43.94-47.03
  CHB   253       198/55              33.98 ± 12.07   32.49-35.48
  LC    248       196/52              50.26 ± 13.29   48.60-51.92
  HCC   122       101/21              53.72 ± 12.50   51.48-55.96

Comparison of age among groups: F = 83.216, *P* \< 0.01; comparison of sex among groups: *χ^2^* = 60.296, *P* \< 0.01. AHB: Acute hepatitis B virus infection; CHB: Chronic hepatitis B virus infection; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma.

***Frequency distribution of* TLR7 *gene copy number***

A reference category was chosen based on the median *TLR7* CN obtained in the female and male control groups (CN = 2 for females and CN = 1 for males), as previously described\[[@B19]\]. Based on the reference category, the risk of disease progression associated with the absolute *TLR7* CN was estimated by comparing cases and controls that were categorized as CN \> 2 or CN ≤ 2 for females and as CN \> 1 or CN ≤ 1 for males. The frequency distributions of *TLR7* CNs of the different patient groups are shown in Figure [1](#F1){ref-type="fig"}.

![Frequency distribution of *TLR7* gene copy numbers in male and female patients. The chronic group includes patients with chronic hepatitis B viral hepatitis, liver cirrhosis, and hepatocellular carcinoma. A: Male patients; B: Female patients.](WJG-23-1602-g001){#F1}

We examined the single-locus association between *TLR7* CN and susceptibility to chronic HBV infection. *TLR7* CNs were significantly different between the acute and chronic group in both male and female patients (males: *χ^2^* = 37.682, *P* \< 0.001; females: *χ^2^* = 22.063, *P* \< 0.001). As shown in Table [3](#T3){ref-type="table"}, low *TLR7* CN was significantly associated with chronic HBV infection in males (OR = 0.329, 95%CI: 0.229-0.473) and females (OR = 0.292, 95%CI: 0.173-0.492). We also compared the *TLR7* CN distributions of the CHB, LC, and HCC groups, but there were no significant differences among the three groups (Table [4](#T4){ref-type="table"}). HBeAg can play a role of immune regulation which is associated with the outcome of HBV infection. E antigen was used as an important index of HBV replication and infection. We divided patients into two groups according to e-antigen titers (0-1 IU/mL *vs* \> 1 IU/mL). However, titer levels did not vary significantly among patient groups (Figure [2](#F2){ref-type="fig"}).

![Frequency distribution of *TLR7* gene copy numbers in males and females according to e-antigen titer. Patients were divided into two groups according to the titer of e antigen: HBeAg negative (0-1 IU/mL) and HBeAg positive (\> 1 IU/mL). A: Male patients; B: Female patients.](WJG-23-1602-g002){#F2}

###### 

Estimated risk of *TLR7* copy number in the development of chronic hepatitis B virus infection

  **Gender**   **CN**   **Chronic group**   **Acute group**   **OR**   **95%CI:**   ***P* value**
  ------------ -------- ------------------- ----------------- -------- ------------ ---------------
  Male         \< 1     337                 68                0.33     0.23-0.47    \< 0.001
  \> 1         158      97                                                          
  Female       \< 2     96                  63                0.29     0.17-0.49    \< 0.001
  \> 2         32       72                                                          

CN: Copy number.

###### 

Frequency distribution of *TLR7* copy number in chronic hepatitis B virus infection groups

  **Gender**   **CN**   **CHB**   **LC**   **HCC**   ***χ*^2^**   ***P* value**
  ------------ -------- --------- -------- --------- ------------ ---------------
  Male         \< 1     137       137      63        1.923        0.382
               \> 1     61        59       38                     
  Female       \< 2     39        42       15        1.557        0.459
               \> 2     16        10       6                      

CN: Copy number; CHB: Chronic hepatitis B virus infection; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma.

DISCUSSION
==========

The disease spectrum of HBV infection ranges from acute HBV infection to chronic HBV carrier to chronic hepatitis, liver cirrhosis, and HCC. Many studies have provided evidence to support the idea that host genetic variation and immunity play important roles in determining the outcome of HBV infection\[[@B20]\]. The gene for Toll-like receptor TLR7 is located on the X chromosome and so experiences sex-linked inheritance. Therefore, analysis of *TLR7* CNVs suggested that the data should be separated according to gender. *TLR7* CNVs have been previously found to be associated with SLE\[[@B20]\], while Lund et al\[[@B21]\] found that TLR7 is involved in the body\'s antiviral immune response. In addition, some researchers believe that TLR7 represents a new sensor of viral infections\[[@B22]\]. However, its role in HBV infection has not been previously determined. We therefore designed this study to explore the association between *TLR7* CNVs and chronic HBV susceptibility. In a previous study, we found that up-regulation of TLR7 is essential for serological clearance of hepatitis B surface antigen in HBV infection. The results in the current study revealed that low *TLR7* CNs were significantly associated with chronic HBV infection in both males and females, suggesting that elimination of HBsAg is more difficult with reduced levels of TLR7. This indicates that a reduction in *TLR7* CN is a risk factor for chronic HBV in Han Chinese patients. Hui et al\[[@B23]\] found that increased expression of TLR7 in the recovery phase may be involved in the clearance of HBsAg in patients with CHB. García-Ortiz et al\[[@B19]\] found that *TLR7* mRNA levels correlated significantly with *TLR7* CN, suggesting that an increase in *TLR7* gene dosage results in the up-regulation of *TLR7* mRNA expression in humans as well as in murine models of lupus. Moreover, Xu et al\[[@B24]\] found that PBMCs and pDCs from CHB patients exhibited diminished capacities to produce IFN-α in response to TLR7 activation. The fact that TLR7 is expressed in pDCs rather than in mDCs indicates that pDCs are potentially involved in fighting against viral infections. Therefore, reduced expression of TLRs in pDCs of CHB patients may lead to functional defects, as demonstrated by diminished production of IFN-α, resulting in persistent HBV infection. We also found that the replication system is adapted to generate high levels of virions without stimulating the innate immune system. Secreted viral proteins (HBsAg and HBeAg) suppress innate responses through inhibition of TLR signaling, which leads to a weak adaptive immune response with an exhausted phenotype that is incapable of inducing viral elimination\[[@B25]\]. Our experiment aims to study the relationship between the two indicators at a gene level. We found no association between TLR7 copy number and titer of the HBV e antigen, which implied that there was no correlation at a gene level between the two indicators.

In conclusion, this was the first study to independently analyze the relationship between *TLR7* CNVs and susceptibility to chronic HBV. Our findings indicate that low copy numbers of the *TLR7* gene may represent a risk factor for chronic HBV infection. Further replication and functional studies are necessary to confirm these results. In particular, as the biological functions of *TLR7* CNVs in HBV infection have not been fully elucidated, further research is required to determine the mechanistic basis by which *TLR7* CNVs affect the immune response.

COMMENTS
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Background
----------

More and more research suggest that the outcome of hepatitis B virus (HBV) infection is influenced by not only the virus but also the host\'s immune response and genetic diversity, including SNPs and gene copy number variations (CNVs). TLRs recognize foreign pathogens as well as necrosis of endogenous substances, and play a role in both the innate and acquired immune responses, but the role of Toll-like receptor 7 (TLR7) CNVs in the outcome of HBV infection has not yet been investigated.

Research frontiers
------------------

In humans, CNVs have so far been identified as a hereditable source of susceptibility to complex diseases such as systemic lupus erythematosus type 1 diabetes, HBV infection, and Alzheimer\'s disease. Some researchers believe that TLR7 represents a new sensor of viral infections. However, its role in HBV infection has not been previously determined.

Innovations and breakthroughs
-----------------------------

In this study, the authors found that there were significant differences between the acute patients and chronic patients in TLR7 copy number, with low copy numbers of TLR7 associated with chronic HBV infection in both males and females. This study identified a significant risk factor for chronic hepatitis B infection.

Applications
------------

This study sheds light on the major underlying mechanisms of hepatitis B, which may have future clinical implications.

Peer-review
-----------

This is a really interesting study since TLR7 is involved in outcome of viral infections such as hepatitis C virus, HBV or human immunodeficiency virus, but no evidence is available about the association of CNV in TLR7 and HBV. The authors compared TLR7 CNVs in patients with acute HBV infection and chronic infection and among patients with chronic HBV classified according to disease progression.
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